Summit Therapeutics Inc. (SMMT) reported a significant increase in its net loss for Q1 2026, posting a loss of $189.4 million, or $0.24 per share, compared to $62.9 million, or $0.09 per share, in the same quarter last year. The company, which focuses on oncology therapies, is advancing its lead candidate Ivonescimab for non-small cell lung cancer and colorectal cancer. Despite the financial setback, Summit has secured collaborations with GSK and GORTEC to enhance the clinical evaluation of Ivonescimab.

The wider losses and ongoing clinical trials may impact investor sentiment, particularly as SMMT shares have already seen volatility, trading between $13.83 and $30.98 over the past year. Following the earnings announcement, the stock fell 15.10% to $18.22 in after-hours trading, reflecting market concerns over the company’s financial health and the timing of its clinical milestones.

Investors should closely monitor upcoming trial results and collaborations, as these could significantly influence SMMT’s stock performance and long-term viability in the competitive oncology market.

Source: nasdaq.com